Weill Cornell Medicine researchers have received major new funding to support collaborative efforts spanning clinical trials, precision medicine and drug target discovery with the potential to improve outcomes for patients with challenging cancers.
Researchers at Weill Cornell Medicine have received a $17.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases to discover new approaches to shorten tuberculosis (TB) treatment, potentially making it easier for patients to complete therapy.
Metabotropic glutamate receptors, which are important but difficult drug targets, interact in surprisingly varied ways with their principal regulatory proteins, according to two new studies led by Weill Cornell Medicine investigators.
Weill Cornell Medicine and Rutgers Health in New Brunswick have received a four-year, $3 million grant from the National Institute of Mental Health (NIMH) to build the infrastructure and resources that will accelerate discoveries about HIV-associated brain injury.
Researchers at Weill Cornell Medicine and Hospital for Special Surgery have discovered the stem cells—unspecialized cells that can develop into specific cell types—that give rise to the body’s tendons and ligaments, the tissues connecting muscles and bones. They also found that when these stem cells become hyperactive in the lower spine, they contribute to lumbar spinal stenosis.
A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study by Weill Cornell Medicine investigators.
A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer.
Obesity caused by disrupted stress-hormone rhythms is metabolically very different from obesity caused by a high-fat diet, according to a new preclinical study by Weill Cornell Medicine investigators.
Weill Cornell Medicine investigators have developed a set of molecular tools to regulate the activity of specific genes in one of the most common classes of intestinal bacteria.
Prostate tumors can rewire amino acid metabolism to override the normal brakes on cholesterol production, a process that may fuel hormone therapy resistance, according to a study by Weill Cornell Medicine investigators.
A conceptual framework like the one engineers use for characterizing the transmission of sound and electrical signals can be useful in studying how olfaction—the sense of smell—is influenced by the air flow that carries odor molecules, according to a study led by investigators at Weill Cornell Medicine and the University of Colorado—Boulder.
The new department will be a catalyst for collaborative research at Weill Cornell Medicine, integrating advanced genomics and patient-focused technologies that generate large and complex datasets with computational approaches—including artificial intelligence—that allow researchers to gain unprecedented insights into the drivers of disease.
Brain-resident immune cells that have reached an old-age state called senescence secrete a protein that causes dysfunction in other brain cells, according to a study led by investigators at Weill Cornell Medicine.
Researchers at Weill Cornell Medicine have uncovered how a key Parkinson's protein called LRRK2 shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state.
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine.
A protein secreted by common cancer types makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.
An overactive immune response in the brain may play a role in Dravet Syndrome, a rare and severe genetic epilepsy that typically begins in infancy, according to Weill Cornell Medicine researchers.
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
